TYRA Tyra Biosciences, Inc.
Tyra Biosciences, Inc. (TYRA) is expected to report earnings on November 3, 2026, after the market close. The consensus earnings estimate is a loss of $0.69 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.8% since its last earnings release on August 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Tyra Biosciences, Inc.
Tyra Biosciences Inc. is a precision oncology company. It focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company's lead product candidate includes TYRA-300. Tyra Biosciences Inc. is based in CARLSBAD, Calif.
Sector
Healthcare
Industry
Biotechnology